Axsome Therapeutics to Present at Biotech Showcase 2018 NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...

Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine Incorporates new molecular entity for migraine and Axsome’s MoSEIC™ technology Potential for superior efficacy as compared to current treatments FDA Pre-IND meeting written guidance received Issued...